• to lower the risk of significant cardiovascular (coronary heart and blood vessel) issues in adults with style two diabetes and cardiovascular diseaseThis led Novo Nordisk to carry out more analysis into larger dosages of semaglutide especially for weight administration.Just one company formally makes name-manufacturer semaglutide with FDA appro